The Impact of Vyxeos Liposomal on patients with t-AML and AML-MRC – The French Experience

Explore the outcomes of 103 patients treated with Vyxeos Liposomal in this French multicentric cohort. The study presents multiple efficacy endpoints, including MRD-negativity prior to HSCT, and contributes to the current understanding of the Vyxeos Liposomal tolerability profile.

Prescribing Information can be found at the top of this page. Adverse event reporting is available at the bottom of this page.

Topics: Safety Vyxeos Liposomal Data

ADVERSE EVENTS REPORTING

Adverse events should be reported. Reporting forms and information for the UK can be found at https://yellowcard.mhra.gov.uk/

For Ireland, reporting forms and information can be found at: www.hpra.ie

Adverse events should also be reported to Jazz Pharmaceuticals at AEreporting@jazzpharma.com

UK-VYX-2100176 | September 2021